Abbott has received FDA clearance and CE Mark for Ultreon 3.0, an advanced AI-powered optical coherence tomography (OCT) system that enhances coronary artery disease treatment. Ultreon 3.0 combines high-resolution imaging with AI to help doctors accurately size and position stents during minimally invasive procedures, improving patient outcomes and reducing risks. The system offers faster, clearer imaging with less contrast, benefiting patients with kidney issues, and supports complex coronary interventions with streamlined workflow and real-time guidance. This innovation represents a significant advancement in precision-guided heart care and is expected to improve the treatment of over 1.4 million PCI procedures annually in the U.S. and Europe.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
